EXTON, Pa., April 5 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that it will release its earnings results for its third quarter ended March 31, 2010 at 7:30 A.M. Eastern Time on Thursday, April 22, 2010.
To participate in the teleconference call, dial 1-612-332-1210. The teleconference call will also be available for replay starting Thursday, April 22, 2010 at 11:00 A.M. Eastern Time through Thursday, April 29, 2010 at 11:59 P.M. Eastern Time by dialing 1-800-475-6701 with an access code of 152075.
Cautionary Note for Forward-Looking Statements. This press release as well as other Company press releases contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the ThromCat(TM) product, the Company's success in distributing its products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, Synthes' success in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer,
+1-484-713-2100
Web site: http://www.kenseynash.com/
